In vitro: Tenapanor exhibits human and rat NHE3 with IC50 values of 5 and 10 nM, respectively. Human intestinal transporters NHE1, NHE2, TGR5, ASBT, and Pit-1 and the sodium-dependent phosphate transporter NaPiIIb are not inhibited by tenapanor at concentrations up to 10 to 30 μM.
In vivo: Tenapanor plays a prominent role in sodium handling in the gastrointestinal tract and kidney. It acts exclusively in the gastrointestinal tract to inhibit sodium uptake when administered orally to rats. Average plasma Cmax values of tenapanor in rats and humans are less than 1 ng/mL with negligible area under the curve at doses of up to 30mg/kg in rats, 10mg/kg in dogs, and 900 mg in humans. Dose-dependent reductions in urinary sodium and increases in fecal sodium and luminal fluid mass are observed upon administering single doses of tenapanor to rats. Chronic administration of tenapanor to rats fed with standard chow (0.49% NaCl) causes a sustained reduction of urinary sodium and increase in fecal sodium.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||10 mM in DMSO|
The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia.
Block GA, et al. Nephrol Dial Transplant. 2018 Apr 3. PMID: 29617976.
A common NHE3 single-nucleotide polymorphism has normal function and sensitivity to regulatory ligands.
Yin J, et al. Am J Physiol Gastrointest Liver Physiol. 2017 Aug 1;313(2):G129-G137. PMID: 28495802.
|Related Sodium Channel Products|
Levobupivacaine is a reversible neuronal sodium channel inhibitor.
PF-05089771 is a selective Nav1.7 channel blocker that interacts with the voltage-sensor domain (VSD) of domain IV.
PF-01247324 is a novel selective and orally bioavailable Nav 1.8 channel blocker with an IC50 of 196 nM for recombinant human Nav1.8 channel.
GS967, also known as GS-458967, is a potent and selective blocker of cardiac late sodium current (late INa) with IC50 values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, respectively.
PF-05089771 Tosylate is a selective and potent inhibitor of the human voltage-gated sodium ion channel Nav1.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.